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Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors
dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin,
tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin,
fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to
culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis,
and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show
the existence of a marked difference in the susceptibility to several antimicrobial agents depending on from
where E. coli was isolated, with higher levels of resistance in isolates from medical devices, the respiratory
system, and the skin and soft tissues; a higher resistance percentage in men than in women; and the existence
of a clear difference in antimicrobial resistance with an age influence that cannot be explained merely by means
of an increase of resistance after exposure to antimicrobials. Both men and women show increases in resistance
with age, but while women show constant levels of resistance or slight increases during childbearing age and
greater increases in the premenopausal age, men show a marked increase in resistance in the pubertal age. In
conclusion, an overwhelming amount of data reveals the great adaptation capacity of E. coli and its close
interaction with the host. Sex, age, and the origin of infection are determining factors with the ability to
modulate antimicrobial resistances.
Escherichia coli is a commensal microorganism in humans
and in many different animal species (23, 32). Structural factors
such as the presence of fimbriae and adhesins confer the bac-
teria adherence ability to epithelial cells and allow its persis-
tence in the colonized areas, mainly in the gastrointestinal tract
(2, 36). In addition, these factors are adapted to different
habitats or species (8, 10, 32). The wide biochemical flexibility
that E. coli exhibits in its use of different carbon sources as
nutrients is another evidence of its successful adaptability. This
nutritional and adaptive flexibility has enabled it to acclimatize
to new environments and to colonize countless niches (32, 36).
For all these reasons, this organism is one of the main
pathogens isolated in samples of various kinds, from urinary
tract infections to meningitis (7). This variety illustrates the
different relationships between E. coli and its host and also the
different physiological profiles and virulence factors it has de-
veloped, including antimicrobial resistance (20, 31, 38).
Under the hypothesis that both E. coli and the antimicrobial
pressure exerted on this microorganism can be modulated by
factors dependent on the host, the aim of this paper is to
describe the distribution of antimicrobial resistance of E. coli
isolated in our region according to culture site and patient age,
gender, and location, i.e., samples originating from hospital-
admitted patients versus samples from the community, and to
study the possible relationships observed.
MATERIALS AND METHODS
This is a retrospective study of antimicrobial resistance in E. coli from patients
from the Comunitat Valenciana, a state in Spain with a surface equal to 23,255
km2 and a population of 5,029,601. Samples were obtained from January 2007 to
October 2009. Data were retrieved from the Comunitat Valenciana Microbio-
logical Surveillance Network (RedMIVA), which daily compiles and analyzes
information from 25 microbiology laboratories that manage more than 90% of
the total population (13, 24, 25).
Studied antimicrobials included amikacin (AMK), tobramycin (TOB), ampi-
cillin (AMP), amoxicillin clavulanate (AMC), cefuroxime (CXM), cefoxitin
(FOX), cefotaxime (CTX), imipenem (IPM), ciprofloxacin (CIP), fosfomycin
(FOF), nitrofurantoin (NIT), and trimetoprim-sulfametoxazole (STX).
Microbial identification and antimicrobial susceptibility testing were per-
formed according to laboratory standard procedures conforming to CLSI anti-
microbial susceptibility breakpoints, either by regular biochemical reactions and
agar diffusion susceptibility tests or automated methods. Susceptible and inter-
mediate isolates were grouped together for statistical analysis.
Samples were classified in the following groups: abscesses, digestive system,
urine, genitourinary system, medical devices, bones and deep tissues, prostatic
fluid, respiratory system, blood, and skin and soft tissues.
For the study of the distribution of resistance according to sex and age, groups
were established every 5 years, except for the first group, which included patients
less than 1 year old, and the last group, which included all patients aged 85 years
or more.
E. coli isolates were considered of nosocomial origin when the sample was
obtained from a hospitalized patient.
Statistical analysis. For each available covariate, a logistic regression model
was performed for antimicrobial resistance. The relationship with age as a con-
tinuous variate was expressed in the following model: Yi  binomial(pi; ni),
logit(pi)  0  1  xi, where Yi is the number of resistant isolates in the age
group, ni is the total number of observations in this group, pi is the probability
that an isolate is resistant for the age group, 0 and 1 are the regression
parameters being estimated, and xi is the covariate.
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To analyze the differences between several categories for the remaining fac-
tors, the logistic regression was expressed as Yi  Binomial(pi; ni), logit(pi) 
  i, subject to the restriction i  0, where  is the global value and i is
the effect of the category i.
Additionally, a complete multivariate model incorporating all the covariates
was also analyzed and compared with partial models to assess the relevance of
each factor.
Bayesian inference was planned in all situations. Markov chain Monte Carlo
(MCMC) simulation was employed to estimate the model parameters (12). We
ran all these models in WinBUGS version 1.43 (34). To compare the adjustment
of the different models, we used the deviance information criterion (DIC). DIC
is a measure of model fit penalized by the complexity of the model, and its value
is calculated by adding the effective number of parameters to the posterior mean
deviance of the model. The “best fit” model is the one with the smallest DIC
value (33). Differences of less than 3 indicate that the two models are indistin-
guishable, greater differences indicate that the poorer model has considerably
less support, and differences of more than 10 indicate that the poorer model has
essentially no support (6).
In order to fully manage the statistical modeling, prior distributions were
established for the parameters. Noninformative prior knowledge was considered
with normal distributions with large variances for covariate parameters.
RESULTS
The numbers of isolates varied according to the antimicro-
bial tested, between 141,583 for AMC and 107,855 for CTX.
Urine samples comprised the group with the greater amount of
isolates and comprised 80% of all isolates from women. This
group presented two crests of incidence in the number of
isolates, one at the reproductive age and the other after meno-
pause. In men, urine samples represented 60% of all isolates,
showing a continuous increase in the number of isolates
through age. The number of isolates from community patients
was higher than that from hospital-admitted patients.
Resistance according to patient location: hospital-admitted
versus community patients. The comparison of percentages of
resistance between hospitalized and community patient sam-
ples revealed a greater proportion of resistant organisms in the
hospitalized group for all antimicrobials studied except for
FOF, which shows the greatest resistance in the community
population, and for NIT and IPM, for which differences are
almost nonexistent (Table 1).
However, there was a group of samples in which the resis-
TABLE 1. Antimicrobial resistance in community patients versus
hospital-admitted patients
Antimicrobial
% (no.) of samples from
community vs hospital-
admitted patients with
antimicrobial resistance
DICa
Different
probabilities
Equal
probabilities
Amikacin 0.3 (98,052) vs 0.5 (30,390) 18.33 32.31
Amoxicillin
clavulanate
6.1 (107,962) vs 9.2 (33,621) 24.44 396.27
Ampicillin 64.8 (91,603) vs 71.4 (26,939) 26.24 433.85
Cefotaxime 8.6 (81,603) vs 12.7 (26,252) 24.51 391.37
Cefoxitin 3.1 (89,307) vs 5.9 (29,172) 22.83 433.15
Cefuroxime 11.2 (107,835) vs 17.2 (33,680) 25.32 822.20
Ciprofloxacin 31.6 (107,142) vs 37.0 (33,481) 26.85 359.22
Fosfomycin 2.4 (94,526) vs 1.8 (20,473) 21.26 48.28
Imipenem 0.1 (98,177) vs 0.2 (30,888) 16.39 15.00
Nitrofurantoin 1.8 (94,297) vs 1.8 (20,619) 21.04 19.02
Tobramycin 6.2 (103,535) vs 7.8 (32,174) 23.91 120.71
Cotrimoxazole 33.7 (100,875) vs 37.5 (28,705) 26.67 162.75
a DIC values obtained for models with different and equal probabilities be-
tween both groups. Boldface type indicates the models with substantial differ-
ences. Different probabilities, significant differences between groups; equal prob-
abilities, no significant differences between groups.
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tance was against the general trend and was higher in commu-
nity samples than in hospital samples, including AMC in ab-
scesses (12.7% [n  393 samples] versus 7.2% [n  1,125
samples]), CIP in medical devices (63.4% [n  161 samples]
versus 49.3% [n  538 samples]), and TOB in bone and deep
tissue samples (10.4% [n  3,760 samples] versus 8.5% [n 
4,915 samples]), with lower DIC values for the two-group
model.
Resistance according to patient sex and culture site. In the
comparison of antibiotic resistance according to culture site
and patient sex, respiratory and medical device samples from
both men and women and skin and soft tissue samples from
men had the highest percentages of resistance. Genitourinary
samples from both sexes as well as urine samples from women
presented the lowest percentages (Tables 2 and 3).
The differences observed between the different types of sam-
ples in each sex presented lower DIC values, except for IPM in
men and for AMK and FOF in women.
The resistance range observed for each antibiotic was very
variable, and less resistance was frequently found in samples
from women, while greater resistance was frequently found in
samples from men. Figure 1 illustrates these differences in CIP
and CXM.
Resistance according to sex and age. In terms of the distri-
bution of resistance according to age and sex, the various
antimicrobials exhibited different patterns in men and women,
except for IPM, with a higher percentage of resistance in men
(see the tables in the supplemental material). These differ-
ences are the most evident in those antimicrobials with higher
resistances.
A poor fit was obtained through the use of data adjustment
using linear regression (Fig. 2), while a logistic regression was
better adapted, justifying different models for men and women
according to the calculated DIC (Table 4), except for IPM.
The patterns observed for the different antimicrobials are
very similar in women, with constant levels of resistance or
slight increases during childbearing age and higher levels in the
premenopausal age. In men, although various patterns were
observed, they are all very similar, with a marked increase in
resistance in the pubertal age that is better appreciated in
antimicrobials with higher resistance percentages, such as cip-
rofloxacin, cotrimoxazole, or cephalosporins (Fig. 2).
Multivariate analysis. Four different statistical models were
created for each antimicrobial in order to explain which vari-
ates were relevant to antimicrobial resistance. All of them
contemplated age as a continuous variate. The first model
TABLE 3. Antimicrobial resistance distribution according to sample type in men
Antimicrobial
% (no.) of samples from men with antimicrobial resistance by sample type DICa
ABS DIS GUS MED URI BDT PROb RES BLO SST Differentprobabilities
Equal
probabilities
AMK 0.1 (907) 0.7 (1,382) 0 (208) 1.5 (329) 0.4 (22,987) 0.7 (4,102) 0.8 (589) 0.5 (1,675) 0.7 (3,297) 0.6 (994) 55.5 59.2
AMC 7.8 (931) 9.5 (1,618) 7.5 (213) 13.2 (340) 7.2 (25,037) 13.6 (4,576) 5.4 (610) 15.7 (1,831) 12.8 (3,793) 12.2 (1,028) 87.2 452.8
AMP 73.7 (693) 69.4 (1,400) 66.5 (203) 84.8 (297) 72.2 (20,806) 78.6 (3,519) 67.0 (466) 83.2 (1,467) 74.8 (3,239) 78.0 (836) 92.6 279
CTX 10.5 (842) 14.0 (1,246) 9.5 (179) 20.2 (267) 11.6 (18,292) 15.5 (3,679) 9.0 (489) 17.5 (1,443) 15.1 (3,154) 18.7 (754) 88 202.1
FOX 3.9 (900) 6.3 (1,585) 1.5 (200) 8.2 (340) 4.3 (19,600) 7.5 (4,461) 4.3 (586) 10.3 (1,761) 7.4 (3,600) 8.2 (995) 81.4 276.6
CXM 14.1 (930) 17.1 (1,643) 9.7 (216) 25.2 (353) 15.4 (24,974) 20.6 (4,619) 11.3 (619) 24.5 (1,856) 21.3 (3,759) 22.5 (1,031) 91.9 334.7
CIP 28.2 (928) 26.1 (1,620) 26.3 (213) 52.8 (358) 42.1 (24,762) 41.9 (4,575) 34.4 (607) 50.4 (1,866) 42.1 (3,795) 45.9 (1,026) 96.9 441.2
FOF 0.4 (242) 1.6 (250) 0 (33) 2.7 (147) 3.0 (24,143) 1.9 (1,271) 0.5 (195) 1.8 (390) 1.7 (722) 3.4 (233) 53.8 69.6
IPM 0 (872) 0.1 (1,552) 0 (202) 0.3 (340) 0.1 (22,849) 0.2 (4,447) 0.2 (562) 0.2 (1,800) 0.2 (3,605) 0.1 (929) 41.5 32.7
NIT 0.7 (288) 0.4 (277) 0 (23) 3.8 (159) 2.3 (24,191) 2.3 (1,158) 2.0 (196) 3.1 (422) 4.2 (662) 4.0 (302) 57 67.9
TOB 6.4 (918) 6.3 (1,584) 5.9 (203) 12.7 (354) 8.6 (24,040) 9.6 (4,520) 4.7 (600) 10.7 (1,704) 8.6 (3,697) 11.2 (1,028) 85.3 130.4
STX 34.0 (579) 33.5 (1,291) 39.7 (136) 42.3 (324) 37.8 (23,965) 40.6 (3,713) 34.1 (446) 42.4 (1,484) 38.9 (2,989) 45.4 (801) 94.5 137.9
a DIC values obtained for models with different and equal probabilities between both groups. Boldface type indicates the models with substantial differences.
Different probabilities, significant differences between groups; equal probabilities, no significant differences between groups.
b PRO, prostatic fluid.
FIG. 1. Cefuroxime and ciprofloxacin resistance in women and men according to culture site. X, men; O, women; ABS, abscesses; DIS, digestive
system; URI, urine; GUS, genitourinary system; MED, medical devices; BDT, bones and deep tissues; RES, respiratory system; BLO, blood; SST,
skin and soft tissues.
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FIG. 2. Antimicrobial resistance according to age and gender. Men, black line; women, black line with exes; man model, red dotted line; woman
model, red line; joint model, black dotted line.
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included all the covariates, i.e., sex, hospitalization, and culture
site, while the other three lacked one of them. The analysis
demonstrated that every factor was needed to correctly repre-
sent antimicrobial resistance, except with FOF, for which the
addition of culture site to the model did not provide any sig-
nificant improvement, and IPM, for which no significant dif-
ferences were observed between models (Table 5).
DISCUSSION
The main findings of this study are (i) the existence of a
marked difference in the susceptibility to several antimicrobial
agents depending on what part of the body the E. coli was
isolated from, (ii) low percentages of resistance to fosfomycin,
nitrofurantoin, amikacin, and imipenem, (iii) the existence of a
clear difference in antimicrobial resistance between isolates
from men and women with an age influence that cannot be
explained merely by means of an increase of resistance after
exposure to antimicrobials, and (iv) a higher resistance per-
centage in men than in women.
This study highlights the differences in susceptibility to an-
timicrobial agents depending on where the E. coli is isolated
from and therefore reinforces previous studies in which an
association between several E. coli phylogroups and infection
sites, or antimicrobial resistance, was found (5, 18, 27). Despite
the large amount of data provided, our study is entirely retro-
spective. Thus, factors such as whether the observed differ-
ences depend solely on the existence of distinct subpopulations
or phylogroups in different sites, on the antimicrobial concen-
tration to which E. coli is exposed in the site, on the activation
of various genes influenced by the environment, or on the
antimicrobial exposure itself are left unsolved (3, 15, 17, 19, 22,
37). Some situations where we have found high rates of resis-
tance, such as the colonization of medical devices, where for-
mation of biofilms is frequent, or colonization of the skin and
respiratory tract, determine circumstances of exposure to low
concentrations of antimicrobials and changes in terms of
growth rate or nutrient intake (11, 17, 35) that can select
subpopulations. On the other hand, the colonization of these
niches requires the initial presence of certain physiological and
phenotypical characteristics (20, 27, 38) so that some phylo-
groups may be favored over others.
As described in other studies (4, 29), levels of antimicro-
bial resistance were higher among hospitalized patients’ iso-
lates than among community isolates, illustrating the higher
antimicrobial pressure that enhances the selection for resis-
tant strains and the transmission of resistance mechanisms
(23, 32, 39). Just the opposite occurs with FOF, because it is
a widely and empirically used drug for the treatment of
urinary tract infections in outpatients due to its ease and
convenience of use (9).
Cases in which greater levels of resistance were found in
community samples for both AMC and CIP may illustrate the
abusive use of these drugs for outpatients in our region (26),
while further studies are necessary to find possible causes for
this difference for TOB.
Four drugs, FOF, NIT, AMK, and IPM, maintain very low
resistance regardless of the colonization site or patient sex or
age. For FOF and NIT, the explanation lies in the decreased
fitness of E. coli after acquiring a mutation that confers resis-
tance to these drugs (1, 30), which, as the antimicrobial pres-
sure disappears, allows the strains without the mutation to
grow faster and displace the resistant ones. The explanation for
AMK and IPM is probably the fact that these are very powerful
TABLE 4. DIC for antimicrobial resistance distribution throughout
life according to sex
Antimicrobial
DICa
Separate models Joint model
Amikacin 207.6 227.5
Amoxicillin clavulanate 396.2 762.6
Ampicillin 641.1 1,652.3
Cefotaxime 467.3 890.3
Cefoxitin 360.4 668.6
Cefuroxime 609.9 1,468.4
Ciprofloxacin 858.8 2,181.5
Fosfomycin 327.9 360.2
Imipenem 151.0 148.6
Nitrofurantoin 308.4 340.9
Cotrimoxazole 700.5 920.2
Tobramycin 399.5 696.1
a Separate models (different age curves for men and women) are contrasted
with a joint model (both sexes share the same age curve). Boldface type indicates
the models with substantial differences. Separate models, significant differences
between groups; joint model, no significant differences between groups.
TABLE 5. DIC values for the different multivariate analyses
Antimicrobial
DICa
Complete model Model withouthospitalization Model without sex
Model without
culture site
Amikacin 6,715.73 6,721.76 6,729.28 6,730.02
Amoxicillin clavulanate 72,341.6 72,364.1 72,493 72,822.2
Ampicillin 155,360 155,397 156,062 155,862
Cefotaxime 68,709.6 68,764.7 68,941 68,895.7
Cefoxitin 38,314.3 38,355.3 38,435.6 38,657.4
Cefuroxime 107,189 107,345 107,670 107,514
Ciprofloxacin 167,795 167,809 169,140 168,398
Cotrimoxazole 167,041 167,057 167,229 167,155
Fosfomycin 26,495.2 26,527.4 26,539.9 26,494.1
Imipenem 2,667.9 2,667.9 2,667.1 2,667.62
Nitrofurantoin 19,953.1 19,957.9 19,986.2 19,966.2
Tobramycin 67,017.7 67,025 67,277.8 67,130.2
a Boldface type indicates the models with substantial differences.
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drugs used only in a hospital setting and not as first-line ther-
apy and, therefore, have lower selective pressure due to their
restricted use.
Finally, the biggest surprise of this study was to find different
patterns for men and women in the acquisition of resistance
throughout life. These patterns rule out a model that can be
understood only as an increase of resistance with age due to a
greater exposure to antimicrobials. In contrast, we observed
how puberty is a key point in which a sharp increase in resis-
tance—in all antimicrobials but AMK and IPM—is produced
among men, who end up being the group with the highest
percentage of resistance, whereas there seems to be a slowing
down of resistance in women that is accelerated at premeno-
pausal age. The most striking case is that of CIP, which shows
a large increase of resistance in previously unexposed young
men, since this antimicrobial is not used in children because it
alters growth. Livermore et al. (21) found that the prevalence
of CIP resistance was strongly associated with men with bac-
teremia and, to a lesser extent, age, with a peak of resistance in
the 15- to 44-year age group for men, which perfectly fits with
our own observations.
Gordon et al. found differences in E. coli populations in
humans depending on age and sex from hospitalized patients’
fecal samples, without observing differences in antimicrobial
susceptibility (14). But while this study was based on 266 iso-
lates, ours included over 100,000 isolates. The fact that such
changes have been found in two periods when important hor-
monal and physiological changes occur certainly deserves more
specific studies and could have significant implications in the
decision of which antimicrobial therapy to use.
A possible sample bias in our study is that a large amount of
isolates came from urine samples and that simpler cases might
be treated empirically; therefore, there is a risk that resistant
cases are selected. Interestingly, both the Spanish Society of
Infectious Diseases and Clinical Microbiology and the guide-
lines issued by the Comunitat Valenciana local government
recommend bacterial cultures to be carried out in all cases
except with nonhospitalized healthy young women presenting
uncomplicated cystitis. Thus, if a sample bias occurs, differ-
ences between community and hospitalized patients, and men
and women, would be greater than observed. Another signifi-
cant limitation to our study lies in the origin of infection clas-
sification; since the times from admission or hospital discharge
until infection were not available, isolates were categorized
depending on the patient’s location at the time the sample was
obtained. Thus, community urinary tract infections taking
place during the first 2 days after admission could be classified
as hospital infections. But again, since community infections
present lower levels of resistance, differences between commu-
nity versus hospitalized patients would be greater than those
observed.
To date, we do not know of any other study that describes
this same behavior associated with age and sex in so many
antimicrobials. Thus, discovering whether E. coli is directly
affected by host hormones as suggested by other authors (16,
28) or if it simply gets adapted to the new and changing niche
conditions caused by physiological changes represents an ex-
citing task.
In conclusion, an overwhelming amount of data reveals the
great adaptation capacity of E. coli to its location and its close
interaction with the host. Sex, age, hospitalization, and the
origin of infection are determining factors with the ability to
modulate antimicrobial resistances, as confirmed by multivar-
iate analysis.
Additionally, this work could not have been done without
RedMIVA, which highlights the usefulness of being able to
rely on large databases of microbiological information.
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